Clinical Trials

165 enrolled

Neoplasms

NCT04584112 2023-03-15

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

83 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03639246 2023-02-13

Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

53 enrolled

Ovarian Neoplasms

NCT00976131 2022-10-17

Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

7 enrolled

Breast

Breast Neoplasms

NCT00819221 2022-08-30

AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours

44 enrolled

Other solid neoplasm

Solid Tumors

NCT01673217 2022-08-01

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

18 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01485874 2022-02-15

Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

11 enrolled

Ovarian Neoplasms

NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

15 enrolled 18 charts

DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT01902225 2020-06-09

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

24 enrolled

DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT04213612 2019-12-30

DCV in the Treatment of Recurrence and Refractory Childhood Solid Tumors

Phase 1 Unknown

21 enrolled

Other neoplasm

Unrecognized Condition

NCT02751918 2019-11-22

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

65 enrolled

Ovarian Neoplasms

NCT00846612 2019-09-30

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

15 enrolled

Ovarian Neoplasms, Recurrence

NCT01459380 2019-07-22

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

41 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01281514 2019-07-11

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

21 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00761644 2019-04-11

Doxil, Bevacizumab and Temsirolimus Trial

200 enrolled

Neoplasm Metastasis

NCT02557854 2019-03-19

HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors

Phase 1 Withdrawn

CNSSarcoma

Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoid Tumors

NCT01489371 2019-03-12

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

16 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01214668 2019-01-04

Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors

Other hematologic neoplasmPlasma cell

31 enrolled 17 charts

Other solid neoplasm

Solid Tumors

NCT03591744 2018-12-19

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Phase 1 Withdrawn

Leukemia, Plasma Cell

NCT00744354 2018-01-18

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

32 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01145430 2017-12-22

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

45 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00659178 2017-07-21

Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer

15 enrolled

Ovarian Neoplasms

NCT02262455 2017-02-13

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

32 enrolled

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Fallopian Tube Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT02081495 2016-11-11

A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

35 enrolled

Neoplasms, Ovarian Neoplasms

NCT01227941 2016-10-19

MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)

6 enrolled

Ovarian Neoplasms

NCT01110603 2016-05-05

A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)

12 enrolled

Neoplasms

NCT02131506 2016-02-02

CAELYX

11 enrolled

Breast

Breast Neoplasms

NCT01815294 2015-12-04

A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

54 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms

NCT00770536 2015-09-29

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

103 enrolled

Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms

NCT01490047 2015-06-16

Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas

Phase 1 Withdrawn

Lymphoid

Lymphoma

NCT01715168 2015-01-15

A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer

Phase 1 Unknown

40 enrolled

Neoplasms, Ovarian Neoplasms

NCT01455532 2014-10-22

A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

59 enrolled

Neoplasms

NCT01702129 2014-09-09

Anti-EGFR Immunoliposomes in Solid Tumors

26 enrolled

Other solid neoplasm

Solid Tumors

NCT00183742 2014-05-22

Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)

35 enrolled

Carcinoma, Neoplasms

NCT01202890 2014-01-08

Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

1 enrolled